Genentech has reigned as king of the biotech industry for more than three decades.

A three-hour chat in a San Francisco pub launched the company in 1976. On its first day of trading in 1980, the stock tripled – and has risen 20-fold since. Today, Genentech's portfolio includes three of the world's top-selling biotech drugs – Avastin ($2.5 billion per year), Herceptin ($1.7 billion), and Rituxan ($2.5 billion).

But the king of biotech is now a buyout target. While I don't believe the takeout bodes well for buyer or seller, the deal should mean big profits for biotech investors. Let me explain...

In 1990, Swiss drug company Roche acquired a majority stake in Genentech. Roche became Genentech's exclusive European distributor. Today, Genentech's drugs represent 30% of Roche's pharmaceutical sales. And as Genentech's largest shareholder, Roche has multiplied its money about 40 times in two decades.

As part of the deal, Roche allowed Genentech to maintain the entrepreneurial spirit so critical to its early success. In return, the Big Pharma's financial backing allowed Genentech to focus on making drugs, not meeting Wall Street's quarterly numbers.

The win-win relationship thrived for nearly two decades. But this past Monday, Roche launched a bid to acquire the 44% of Genentech shares it didn't already own.

Apparently, the takeout move caught Genentech executives off-guard. Roche insists it's interested in boosting its research engine... not downsizing. But our inside sources tell us many employees are dusting off their resumes in preparation for a post-merger shakeout. Whether it's voluntary or not, a mass exodus of the Genentech talent pool won't help Roche.

And I think the minimum $40 billion outlay is a mistake. Roche's new trigger-happy CEO, Severin Schwan, led the diagnostics division on several hundred-million-dollar buyouts. Now he's courting another acquisition when the money could be better spent on research.

As I wrote earlier, Genentech is more like a Big Pharma player than the tiny biotech it once was. It focuses on expanding its existing drugs in new indications, rather than discovering new drugs. Since Roche already reaps the benefits of Genentech's portfolio, gobbling up the rest of the shares adds little value.

And Roche is going to have to pay up. The company's initial $89-per-share offer gave a measly 9% premium to Genentech's shareholders. The market thought it was a low-ball bid and pushed shares as high as $94.50. My guess is the bidding will stop around $100 per share, valuing Genentech at $100 billion.

While I believe the bid is a bad move for Roche – and not a great proposal for Genentech shareholders – this mega-deal is actually good for the entire biotech industry... and its investors.

With Genentech gone, the top of the biotech food chain is empty. Many investors will be searching for new spots to park their biotech cash. And sector valuations are on the rise. Both major biotech indexes – the Nasdaq Biotech Index and AMEX Biotech Index – are up more than 7% in just a few weeks.

Small-cap biotechs are cheap right now. So I'd be willing to bet the sector could jump 25% or more in the coming months. And big-cap names like Biogen (BIIB), Genzyme (GENZ), and Elan (ELAN) have jumped to the top of Big Pharma's short list of buyout candidates.

If you're thinking of dabbling in the biotech sector, Roche's bid for Genentech just may be the buy signal you're waiting for.

Legal Notices: Stansberry Research LLC (Stansberry Research) is a publishing company and the indicators, strategies, reports, articles and all other features of our products are provided for informational and educational purposes only and should not be construed as personalized investment advice. Our recommendations and analysis are based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.

Readers should be aware that trading stocks and all other financial instruments involves risk. Past performance is no guarantee of future results, and we make no representation that any customer will or is likely to achieve similar results.

Our testimonials are the words of real subscribers received in real letters, emails, and other feedback who have not been paid for their testimonials. Testimonials are printed under aliases to protect privacy, and edited for length. Their claims have not been independently verified or audited for accuracy. We do not know how much money was risked, what portion of their total portfolio was allocated, or how long they owned the security. We do not claim that the results experienced by such subscribers are typical and you will likely have different results.

Any performance results of our recommendations prepared by Stansberry Research are not based on actual trading of securities but are instead based on a hypothetical trading account. Hypothetical performance results have many inherent limitations. Your actual results may vary.

Stansberry Research expressly forbids its writers from having a financial interest in any security they recommend to our subscribers. And all Stansberry Research (and affiliated companies), employees, and agents must wait 24 hours after an initial trade recommendation is published on the Internet, or 72 hours after a direct mail publication is sent, before acting on that recommendation.

Stansberry Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties.
This website may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web),
in whole or in part, is strictly prohibited without the express written permission of Stansberry Research, LLC. 1217 Saint Paul Street, Baltimore MD 21202.